關(guān)鍵詞

PD-1 單抗 肝損傷 過(guò)敏 免疫 人源化單抗

?

#今日行業(yè)熱點(diǎn)#

①Lanect子刊：Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: an open-label, single-centre phase 2 study

單藥PD-1單抗sintilimab用于局部晚期直腸癌患者的有效性和可耐受性分析

DOI :10.1016/S2468-1253(22)00439-3

?

②Journal of Thoracic Oncology：Efficacy, Safety, and Biomarker Analysis of Neoadjuvant Camrelizumab and Apatinib in Patients with Resectable Non-Small-Cell Lung Cancer: A Phase 2 Clinical Trial

卡曲瑞珠單抗（一種抗PD-1抗體）聯(lián)合阿帕替尼用于可切除晚期非小細(xì)胞肺癌（NSCLC）的II期臨床試驗(yàn)分析

DOI :10.1016/j.jtho.2023.02.019

?

③Journal of Hepatology：Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury

干擾素誘導(dǎo)的IL-10在慢性肝損傷期間驅(qū)動(dòng)全身T細(xì)胞功能障礙

DOI :10.1016/j.jhep.2023.02.026

?

④Cell子刊：LMAN1 is a receptor for house dust mite allergens

過(guò)敏原識(shí)別過(guò)程新靶點(diǎn)——LMAN1是室內(nèi)塵螨過(guò)敏原的受體

DOI :10.1016/j.celrep.2023.112208

?

⑤Nature Communications：CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy

CDK4/6抑制觸發(fā)ICAM1驅(qū)動(dòng)的免疫應(yīng)答，并使LKB1突變肺癌對(duì)免疫治療增敏

DOI :10.1038/s41467-023-36892-4

?

⑥Cell子刊：Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade

腫瘤中纖維細(xì)胞簇的鑒定揭示了PD-L1阻斷在抗腫瘤免疫中的作用

DOI :10.1016/j.celrep.2023.112162

?

⑦人源化抗PD-L1單克隆抗體阿得貝利單抗獲批，成為我國(guó)首個(gè)獲批小細(xì)胞肺癌適應(yīng)癥的自主研發(fā)PD-L1抑制劑

?

⑧一種用于杜氏肌營(yíng)養(yǎng)不良癥(DMD)的“first-in-class”新藥Vamorolone在英國(guó)MHRA提交上市許可申請(qǐng)

⑨一種潛在的“best-in-class”、高親和力、IgG1亞型的全人源單克隆抗體Cosibelimab用于皮膚鱗狀細(xì)胞癌（cSCC）的上市申請(qǐng)獲FDA受理

?

⑩北京大學(xué)腫瘤醫(yī)院領(lǐng)銜研發(fā)的一款基于重組人源化抗體獲得的靶向CLDN18.2免疫PET探針用于胃腸道腫瘤無(wú)創(chuàng)成像的研究發(fā)表相關(guān)研究數(shù)據(jù)，成果顯著

?

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！

?